Novo Nordisk stock plunges 20% after a trial of its latest weight loss drug disappoints [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
Eli Lilly, a competitor in the market for GLP-1 weight loss drugs, was up about 5%. Novo Nordisk's stock suffered its biggest one-day slide on record after its latest obesity drug trial disappointed investors hoping for another blockbuster weight-loss drug. The Ozempic-maker's stock plunged 21% to trade at $82.03 per share shortly after the opening bell on Friday morning, hitting its lowest level in over a year. The losses come after the Danish drugmaker published a highly-anticipated study on its experimental obesity drug CagriSema. The results showed that the drug helped participants lose an average of 22.7% of their weight after taking it for over a year, below the drugmaker's expectations for 25% weight loss. The two-drug treatment combines semaglutide, the appetite-suppressing active ingredient in the company's blockbuster weight loss drugs Ozempic and Wegovy, with cagrilintide, an experimental drug that targets a gut hormone called amylin to make people feel full whil
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- US Approves First Drug Treatment For Sleep Apnea [Barron's]Barrons
- FDA approves weight-loss drug Zepbound for obstructive sleep apnea [CNN]CNN
- FDA approves weight loss drug Zepbound for sleep apnea [MSNBC.com]MSNBC.com
- FDA Approves First Medication for Obstructive Sleep Apnea [Yahoo! Finance]Yahoo! Finance
- Zepbound Approved For Sleep Apnea [Forbes]Forbes
LLY
Earnings
- 10/30/24 - Miss
LLY
Sec Filings
- 12/17/24 - Form 4
- 12/17/24 - Form 4
- 12/17/24 - Form 4
- LLY's page on the SEC website